Health Care-Related Economic Burden of Polycystic Ovary Syndrome in the United States: Pregnancy-Related and Long-Term Health Consequences
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Context: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of reproductive-aged women, affecting approximately 5% to 20% of women of reproductive age. The economic burden of PCOS was previously estimated at approximately $3.7 billion annually in 2020 USD when considering only the costs of the initial diagnosis and of reproductive endocrine morbidities, without considering the costs of pregnancy-related and long-term morbidities. Objective: This study aimed to estimate the excess prevalence and economic burden of pregnancy-related and long-term health morbidities attributable to PCOS. Methods: PubMed, EmBase, and Cochrane Library were searched, and studies were selected in which the diagnosis of PCOS was consistent with the Rotterdam, National Institutes of Health, or Androgen Excess and PCOS Society criteria, or that used electronic medical record diagnosis codes, or diagnosis based on histopathologic sampling. Studies that included an outcome of interest and a control group of non-PCOS patients who were matched or controlled for body mass index were included. Two investigators working independently extracted data on study characteristics and outcomes. Data were pooled using random effects meta-analysis. The I2 statistic was used to assess inter-study heterogeneity. The quality of selected studies was assessed using the Newcastle-Ottawa Scale. Results: The additional total healthcare-related economic burden of PCOS due to pregnancy-related and long-term morbidities in the United States is estimated to be $4.3 billion annually in 2020 USD. Conclusion: Together with our prior analysis, the economic burden of PCOS is estimated at $8 billion annually in 2020 USD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PCOS has a high healthcare-related economic burden”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [62]
In the citing paper
“comprehensive screening and counseling from physicians and greater public awareness can curtail morbidity and reduce the economic burden on both the patient and the healthcare system.”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [62]
In the citing paper
“The diagnosis of PCOS included the ICD-9 and ICD-10 codes, and these have been validated and used in previous epidemiologic studies.6,10,17,27,32,55, 56, 57”
From Increased Prevalence of Adverse Health Outcomes Across the Lifespan in Those Affected by Polycystic Ovary Syndrome: A Canadian Population Cohort (2024) · cites this paper as [27]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Economic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143
Self-citationAzziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Self-citationTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., International PCOS Network, Andersen, M., et al. (2018) · Human Reproduction · doi:10.1093/humrep/dey256 · Cited by 1,593
Self-citationWild, S., Pierpoint, T., McKeigue, P., & Jacobs, H. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.01000.x · Cited by 970
Joham, A. E., Norman, R. J., Stener-Victorin, E., Legro, R. S., Franks, S., Moran, L. J., Boyle, J., & Teede, H. J. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00163-2 · Cited by 838
Azziz, R. (2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002698 · Cited by 573 · cited 1×
“These criteria, commonly referred to as the Rotterdam criteria, require that two of the following three features to be present for the diagnosis: (1) oligo- or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, (3) polycystic ovarian morphology on ultrasound, after the exclusion of other etiologie…”
BackgroundSelf-citationAzziz, R., Marin, C., Hoq, L., Badamgarav, E., & Song, P. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0628 · Cited by 537
Self-citationDahlgren, E., Johansson, S., Lindstedt, G., Knutsson, F., Oden, A., Janson, P., Mattson, L.-A., Crona, N., & Lundberg, P.-A. (1992) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(92)90704-m · Cited by 527
Dahlgren, E., Johansson, S., Lindstedt, G., Knutsson, F., Odén, A., Janson, P. O., Mattson, L.-Å., Crona, N., & Lundberg, P.-A. (1992) · Fertility and Sterility · doi:10.1016/s0015-0282(16)54892-4 · Cited by 470
Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies
Hull, M. G. R. (1987) · Gynecological Endocrinology · doi:10.3109/09513598709023610 · Cited by 427
Deputy, N. P., Kim, S. Y., Conrey, E. J., & Bullard, K. M. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6743a2 · Cited by 347
Qin, J. Z., Pang, L. H., Li, M. J., Fan, X. J., Huang, R. D., & Chen, H. Y. (2013) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-11-56 · Cited by 317
Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis
Kjerulff, L. E., Sanchez-Ramos, L., & Duffy, D. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.03.021 · Cited by 300
Cibula, D. (2000) · Human Reproduction · doi:10.1093/humrep/15.4.785 · Cited by 267
Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2017) · JAMA · doi:10.1001/jama.2017.3439 · Cited by 257
Yu, H.-F., Chen, H.-S., Rao, D.-P., & Gong, J. (2016) · Medicine · doi:10.1097/md.0000000000004863 · Cited by 257
Naderpoor, N., Shorakae, S., de Courten, B., Misso, M. L., Moran, L. J., & Teede, H. J. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmv063 · Cited by 255
Schmidt, J., Landin-Wilhelmsen, K., Brännström, M., & Dahlgren, E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1677 · Cited by 241
Bahri Khomami, M., Joham, A. E., Boyle, J. A., Piltonen, T., Silagy, M., Arora, C., Misso, M. L., Teede, H. J., & Moran, L. J. (2019) · Obesity Reviews · doi:10.1111/obr.12829 · Cited by 211
Palomba, S., Falbo, A., Russo, T., Tolino, A., Orio, F., & Zullo, F. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.10.043 · Cited by 188
Lifestyle Modification Programs in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis
Domecq, J. P., Prutsky, G., Mullan, R. J., Hazem, A., Sundaresh, V., Elamin, M. B., Phung, O. J., Wang, A., Hoeger, K., Pasquali, R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2385 · Cited by 184
Hypertension in Women of Reproductive Age in the United States: NHANES 1999-2008
Bateman, B. T., Shaw, K. M., Kuklina, E. V., Callaghan, W. M., Seely, E. W., & Hernández-Díaz, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036171 · Cited by 135
Gestational diabetes screening with the new IADPSG guidelines: a cost-effectiveness analysis
Mission, J. F., Ohno, M. S., Cheng, Y. W., & Caughey, A. B. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.06.048 · Cited by 111
Kazemi Jaliseh, H., Ramezani Tehrani, F., Behboudi-Gandevani, S., Hosseinpanah, F., Khalili, D., Cheraghi, L., & Azizi, F. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.09.004 · Cited by 80
Perspectives on polycystic ovary syndrome: Is polycystic ovary syndrome research underfunded?
Brakta, S., Lizneva, D., Mykhalchenko, K., Imam, A., Walker, W., Diamond, M. P., & Azziz, R. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01415 · Cited by 76
Self-citationPolycystic Ovarian Syndrome: Long-Term Health Consequences
Zore, T., Joshi, N., Lizneva, D., & Azziz, R. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1603096 · Cited by 72 · cited 1×
“These criteria, commonly referred to as the Rotterdam criteria, require that two of the following three features to be present for the diagnosis: (1) oligo- or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, (3) polycystic ovarian morphology on ultrasound, after the exclusion of other etiologie…”
BackgroundSelf-citationFecundity among women with polycystic ovary syndrome (PCOS)—a population-based study
Persson, S., Elenis, E., Turkmen, S., Kramer, M. S., Yong, E.-L., & Sundström-Poromaa, I. (2019) · Human Reproduction · doi:10.1093/humrep/dez159 · Cited by 62
Hoyos, L. R., Putra, M., Armstrong, A. A., Cheng, C. Y., Riestenberg, C. K., Schooler, T. A., & Dumesic, D. A. (2020) · Journal of Medical Internet Research · doi:10.2196/16541 · Cited by 53
Self-citationLunde, O., & Tanbo, T. (2007) · Gynecological Endocrinology · doi:10.1080/09513590701705189 · Cited by 43
Okoroh, E. M., Boulet, S. L., George, M. G., & Craig Hooper, W. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.10.022 · Cited by 37
Does the risk of diabetes and heart disease in women with polycystic ovary syndrome lessen with age?
Azziz, R. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.09.034 · Cited by 20
Self-citationFamily size in women with polycystic ovary syndrome
Pall, M., Stephens, K., & Azziz, R. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.11.051 · Cited by 14
Self-citation
Research works printed but not linked: 5
- Zawadzki, 1992, Diagnostic criteria for polycystic ovary syndrome; towards a rational approach, 337
- Rohde, 2012, Health Care Expenditures for Uncomplicated Pregnancies, 2009
- Martin, 2019, Births: final data for 2018, Natl Vital Stat Rep., 68, 1
- American College of Obstetricians, Task Force on Hypertension in Pregnancy, 2013, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy, Obstetrics and Gynecology, 1122
- Pourat, 2013, Costs of Gestational Hypertensive Disorders in California: Hypertension, Preeclampsia, and Eclampsia
Cited by
Stener-Victorin, E., Teede, H., Norman, R. J., Legro, R., Goodarzi, M. O., Dokras, A., Laven, J., Hoeger, K., & Piltonen, T. T. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00511-3 · Cited by 495
Teede, H. J., Khomami, M. B., Morman, R., Laven, J. S. E., Joham, A. E., Costello, M., Patil, M., Rees, D. A., Berry, L., Cree, M. G., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00717-8 · Cited by 306
Self-citationCurrent Guidelines for Diagnosing PCOS
Christ, J. P., & Cedars, M. I. (2023) · Diagnostics · doi:10.3390/diagnostics13061113 · Cited by 340
“Despite causing over USD 8 billion in healthcare costs in the United States, accurate US population-based estimates of incidence and prevalence are lacking and as many as 75% of patients with PCOS are unidentified in clinical practice [2].”
BackgroundPolycystic ovary syndrome as a metabolic disease
Helvaci, N., & Yildiz, B. O. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01057-w · Cited by 188
“Women with PCOS are exposed to these metabolic alterations starting from a young age, imposing a high burden on their long-term health and causing a substantial increase in health-care-related costs 4 .”
Adipose Tissue Dysfunction in Polycystic Ovary Syndrome
Bril, F., Ezeh, U., Amiri, M., Hatoum, S., Pace, L., Chen, Y.-H., Bertrand, F., Gower, B., & Azziz, R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad356 · Cited by 123
Self-citation
Metadata
- Authors
- Riestenberg, C., Jagasia, A., Markovic, D., Buyalos, R. P., & Azziz, R.
- Affiliations
- University of California, Los Angeles (US)
- University of Pennsylvania (US)
- Corresponding author
- Azziz, Ricardo
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2021-09-21
- Volume
- 107
- Issue
- 2
- Pages
- 575-585
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W3199422888
- Cited by
- 210
- References
- 36
- Citations by year
- 2026: 58 · 2025: 56 · 2024: 35 · 2023: 37 · 2022: 21 · 2021: 3
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Foundation for Research and Education Excellence
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, economic burden, health care costs, pregnancy complications, long-term health effects
- MeSH terms
- Health Expenditures, Female, Humans, Polycystic Ovary Syndrome, Pregnancy, Pregnancy Complications, United States, Comorbidity, Prevalence, Case-Control Studies, Health Care Costs, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.